Reviewed by Michael Gill, B. Sc.
9 Narcolepsy Clinical Trials Near Me
Top Hospitals for Narcolepsy Clinical Trials
Image of Ohio Sleep Medicine Institute in Ohio.
Ohio Sleep Medicine Institute
Dublin
4Active Trials
9All Time Trials for Narcolepsy
2016First Narcolepsy Trial
Image of Sleep Disorders Center of Alabama in Alabama.
Sleep Disorders Center of Alabama
Birmingham
3Active Trials
11All Time Trials for Narcolepsy
2005First Narcolepsy Trial
Top Cities for Narcolepsy Clinical Trials
Image of Cincinnati in Ohio.
Cincinnati
7Active Trials
Clinical Research SiteTop Active Site
Narcolepsy Clinical Trials by Phase of Trial
Phase 2 Narcolepsy Clinical Trials
4Active Narcolepsy Clinical Trials
4Number of Unique Treatments
71Number of Active Locations
Narcolepsy Clinical Trials by Age Group
Most Recent Narcolepsy Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
10/26/2021
Phase 2
4/9/2021
Phase 4
Top Treatments for Narcolepsy Clinical Trials
Treatment Name
Active Narcolepsy Clinical Trials
All Time Trials for Narcolepsy
First Recorded Narcolepsy Trial
AXS-12 (reboxetine)
2
2
2021
Mazindol
1
1
2021
JZP-258
1
2
2017
FT218
1
2
2016
Driving Decision Aid
1
1
2019
Recently Completed Studies with FDA Approved Treatments for Narcolepsy
Treatment
Year
Sponsor
Solriamfetol 150 mg Oral Tablet
2021
Jazz Pharmaceuticals
ADAIR 10 mg IR tablets
2020
Vallon Pharmaceuticals, Inc.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: October 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Nirogi R, Mudigonda K, Bhyrapuneni G, Muddana NR, Shinde A, Goyal VK, Pandey SK, Mohammed AR, Ravula J, Jetta S, Palacharla VRC. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clin Drug Investig. 2020 Jul;40(7):603-615. doi: 10.1007/s40261-020-00920-8. https://pubmed.ncbi.nlm.nih.gov/323998532 Betz ME, Omeragic F, Meador L, DiGuiseppi CG, Fowler NR, Han SD, Hill L, Johnson RL, Knoepke CE, Matlock DD, Moran R; AUTO Research Team. The Advancing Understanding of Transportation Options (AUTO) study: design and methods of a multi-center study of decision aid for older drivers. Inj Epidemiol. 2021 May 3;8(1):23. doi: 10.1186/s40621-021-00310-4. https://pubmed.ncbi.nlm.nih.gov/339347093 Betz ME, Hill LL, Fowler NR, DiGuiseppi C, Han SD, Johnson RL, Meador L, Omeragic F, Peterson RA, Matlock DD. "Is it time to stop driving?": A randomized clinical trial of an online decision aid for older drivers. J Am Geriatr Soc. 2022 Apr 20. doi: 10.1111/jgs.17791. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/354417004 Betz ME, Hill LL, Fowler NR, DiGuiseppi C, Han SD, Johnson RL, Meador L, Omeragic F, Peterson RA, Matlock DD. "Is it time to stop driving?": A randomized clinical trial of an online decision aid for older drivers. J Am Geriatr Soc. 2022 Jul;70(7):1987-1996. doi: 10.1111/jgs.17791. Epub 2022 Apr 20. https://pubmed.ncbi.nlm.nih.gov/35441700